Kolon Life Sciences has attained approval in South Korea for a first-in-class cell-mediated gene therapy designed to treat osteoarthritis through regeneration of cartilage.
“Kolon has said injection of Invossa has been shown in Phase III trials in Korea to ease the symptoms of about 84% of patients – while 88% of U.S. patients treated with the gene therapy in Phase 2 trials reported improved symptoms for up to two years.”
Find out more about this novel approach to improving Osteoarthritis care:
South Korea OKs First-in-Class Gene Therapy for Osteoarthritis
Learn more about Arthroventions: http://www.arthroventions.com/